PharmD Post-Doctoral Fellowship Program...In January 2015, we launched our “Alnylam 2020” guidance for the advancement and commercialization of RNAi therapeutics as a whole new

1

I N PA RT N E R S H I P WIT H

PharmD Post-Doctoral Fellowship Program

2

1

MESSAGE FROM OUR CMO

On behalf of Alnylam Pharmaceuticals, I would like to thank you for your interest in the Post-Doctoral Pharm.D. Industry Fellowship in partnership with Northeastern University.

At Alnylam, we are leading the advancement of an entirely new class of medicines known as RNA interference, or RNAi. Utilizing this Nobel Prize winning technology, we have developed a robust pipeline through our 3 Strategic Therapeutic Areas (STArs): Genetic Medicines, Cardio-Metabolic, and Hepatic Infectious Diseases.

We pride ourselves in our core values: commitment to people, innovation and discovery, sense of urgency, open culture and passion for excellence, and are seeking Fellows that would thrive in such an environment. Alnylam offers Fellows a unique opportunity to join a company transitioning to a top-tier, independent, commercial stage biopharmaceutical company. The Fellow will be positioned to gain experience in a wide range of functional and therapeutic areas and take on multiple roles within the company. It is truly an exciting time to be at Alnylam and we are thrilled to have PharmD Fellows be a part of the company’s growth. I have no doubts that this will be an invaluable and unparalleled opportunity to begin an exceptional and successful career in the biopharmaceutical industry.

I strongly encourage you to consider Alnylam in your Fellowship selection process and wish you the best in your post graduate interview and application process.

Sincerely,

Akshay Vaishnaw, M.D., Ph.D.Executive Vice President of Research and Development & Chief Medical Officer of Alnylam Pharmaceuticals

1

2

Alnylam was founded in 2002 on a revolutionary vision and bold mission which remain firmly in place today.We are a growing biopharmaceutical company developing novel therapeutics based on RNAi.

3

VISION 2020 (Click to play video)

VISION: Harnessing a revolution in biology for human health®

MISSION: Build a top-tier biopharmaceutical company founded on RNAi

4

RNAi is a natural process of gene silencing that occurs in organisms ranging from plants to mammals. By harnessing the natural biological process of RNAi occurring in our cells, the creation of a major new class of medicines, known as RNAi therapeutics, is on the horizon. RNAi therapeutics target the ‘root’ genetic cause of diseases by potently silencing specific messenger RNA (mRNA), thereby preventing disease-causing proteins from being made. RNAi therapeutics are a class of oligonucleotide or nucleic acid-based drugs that have the potential to treat disease and help patients in a fundamentally new way.

Genes provide cells with the instructions for making proteins, and proteins—or more specifically proteins made abnormally—are

the cause of most human disease. When a gene is silenced, the cell stops making the protein specified by that gene, thereby reducing the occurrence and/or symptoms of disease. RNAi is a natural mechanism for silencing specific genes.

While RNAi was first observed in plants in 1990, the first crucial breakthrough in understanding the RNAi mechanism came from studies in worms. In 1998, the work of Andrew Fire and Craig Mello led to the recognition that long double-stranded RNA (dsRNA) could induce specific gene silencing. Fire and Mello were awarded the Nobel Prize in 2006.

Induction of RNAi using dsRNA quickly became a powerful tool for scientists to

The discovery of RNA interference (RNAi) has been heralded as a major scientific breakthrough and represents one of the most promising advancing frontiers in drug development today.

OUR SCIENCE & TECHNOLOGY

5

study the function of genes in many lower organisms, including worms and fruit flies. However, this approach initially seemed unworkable in mammalian cells, because of the tendency of dsRNA to provoke an immune response and cause cell suicide. Such cell suicide makes biological sense in the true, real-life situation where dsRNA is encountered—namely viral infection—because it aims to prevent replication and spread of the virus to neighboring cells. For a time, however, it was a major obstacle to experimental induction of RNAi in mammalian cells.

This obstacle was overcome by Alnylam scientific founders, who developed a new strategy to trigger RNAi in mammalian cells using relatively small dsRNAs—long enough

to induce RNAi, but small enough to avoid inducing an immune response. Alnylam founders were the first to show that smaller dsRNAs, known as “small interfering RNAs” (siRNAs), bind to messenger RNAs (mRNAs) and silence disease causing genes. These discoveries opened the door for application of RNAi as a new therapeutic strategy. Alnylam was founded in June 2002 with the focus of advancing RNAi therapeutics as a new class of innovative medicines.

6

OUR COMPANY

Alnylam is leading the translation of RNAi as a new class of innovative medicines, with a core focus on RNAi therapeutics geared toward genetically defined targets for the treatment of serious, life-threatening diseases with limited treatment options for patients and their caregivers.

In January 2015, we launched our “Alnylam 2020” guidance for the advancement and commercialization of RNAi therapeutics as a whole new class of innovative medicines. Specifically, by the end of 2020, we expect to achieve a company profile with three marketed products, ten RNAi therapeutic clinical programs—including four in late stages of development —across three Strategic Therapeutic Areas (STArs). Our three STArs include:

Genetic Medicines, RNAi therapeutics for the treatment of rare diseases;

Cardio-Metabolic Disease, RNAi therapeutics for the treatment of unmet needs in dyslipidemia, hypertension, diabetes, and non-alcoholic steatohepatitis (NASH); and

Hepatic Infectious Disease, RNAi therapeutics for the treatment of infectious diseases with liver involvement.

“Alnylam 2020” marks our expected transition from a late-stage clinical development company to a multi-product commercial-stage company with a robust and sustainable development pipeline—a profile that we believe has rarely been achieved in the biopharmaceutical industry.

CapellaClick the screenshot to the left to view our most recent press releases and presentations

http://www.alnylam.com/capella/

7

RNAi RoundtablesClick the screenshot to the left to view our RNAi Roundtable series from this year

PipelineClick the screenshot to the left to view our most current pipeline

“We are thrilled to offer a comprehensive and robust Medical Affairs Fellowship program in partnership with Northeastern University. At Alnylam, we encourage Fellows to proactively engage, provide unique perspectives and play an integral role in all aspects of Medical Affairs. Broad, in-depth, cross-functional experiences will allow Fellows to develop a solid foundation for bringing innovative medicines to patients.”

- Pritesh Gandhi, Pharm.D., Vice President, Medical Affairs

http://www.alnylam.com/product-pipeline/http://www.alnylam.com/our-approach/summer-rnai-roundtable-series/

8

MEDICAL AFFAIRS FELLOWSHIP PROGRAM

The Alnylam Pharmaceuticals and Northeastern University Fellowship offers all aspects of a traditional industry fellowship in the setting of a leading biotechnology company based in the heart of Cambridge, MA. The Fellowship is a two-year program that places an emphasis on RNAi therapeutics toward genetically defined targets for the treatment of serious, life-threatening diseases with limited treatment options.

The core purpose of Medical Affairs at Alnylam Pharmaceuticals is to engage in balanced, in-depth scientific and clinical data generation and exchange with KOLs to bring innovative and value-added health care solutions to patients. Medical Affairs plays a critical role in investigator sponsored trials, publications, continuing medical education and grant support, KOL engagement, health care professional education, medical meeting activities, advisory boards and support for Alnylam sponsored trials, all of which are necessary to ensure the safe, effective and appropriate use of our investigational agents. Our key measures of success include: 1) augment disease awareness efforts through health care educational initiatives to ensure patient access in ongoing clinical trials; 2) accelerate patient recruitment in company-sponsored studies; 3) establish streamlined, relevant and productive registries; and 4) timely submission of primary and secondary manuscripts to high-impact factor journals.

The Fellow will have the opportunity to gain experience in the aforementioned roles through a variety of rotations within the Medical Affairs department, including, but not limited to, Publications, Scientific Communications, Patient Advocacy, Health Economics and Outcomes Research, and Field Medical. The Fellow will also have core rotations with other departments within Alnylam including, but not limited to, Regulatory, Clinical Operations, Commercial, Drug Safety and Pharmacovigilance, and Clinical Development. These elective rotations will allow the fellow to gain insight into the integral and strategic roles of various functions within Alnylam throughout a product’s life cycle.

Additionally, the Fellow will select and assume full responsibility for at least two major projects that are aligned with the strategic vision of Alnylam. The Fellow will contribute to the development and submission of clinical abstracts and papers for publication in high impact factor medical and scientific journals.

Along with the opportunities at Alnylam, the Fellowship will maintain a robust academic component through its partnership with Northeastern University. The Fellow will receive an adjunct clinical faculty appointment and will be responsible for precepting Doctor of Pharmacy candidates. The Fellow will collaborate with other Faculty members on elective courses and lectures as a core function and expectation of this program. Participation in continuing education seminars and planning meetings designed to create a sense of community among the Alnylam/Northeastern University Fellowship community will also be part of the training. Furthermore, the Fellow will have the opportunity to participate in a teaching certificate program offered by Northeastern University.

9

DUTIES & RESPONSIBILITIES

• Serve as a core member of the Medical Affairs team to ensure that activities and initiatives arealigned with company goals and respects/maintains compliance with corporate policies;

• Identify, establish and maintain collaborative relationships with key opinion leaders and institutionsstrategic to product development;

• Increase Alnylam’s visibility with current and future industry leaders, and provide a venue for clinicalresearch that is consistent with company objectives;

• Attend medical/scientific meetings to ensure an in-depth understanding of cutting edge informationthat will help shape our publications and investigator sponsored trials strategies;

• Work with cross functional teams on the development and approval of core clinical material (slidesets, etc.);

• Conduct gap analyses of publication landscapes for disease states relevant to the Alnylam pipeline;

• Implement appropriate publication strategy, provide ideas for generating manuscripts of scientificinterest, write and review manuscripts and abstracts with appropriate clinical analysis;

• Craft, present and implement a publication and investigator-sponsored trial strategic plan;

• Review and provide constructive feedback on the design of investigator sponsored trial protocols;

• Develop and foster relationships with patient advocacy organizations to identify patient needs andensure the patient voice is heard.

FELLOWSHIP QUALIFICATIONS

Graduated from an ACPE accredited Doctor of Pharmacy Program.

The candidate should be driven to have a thorough understanding of disease biology, scientific data, and competitive information in order to develop scientifically rigorous and high quality products and programs. Furthermore, the candidate must possess proficient written and verbal communication skills, as they will be involved in the delivery of oral and written presentations to internal and external audiences on the medical and clinical aspects of a given disease, product, or program. A successful candidate should have the foundation to critically interpret cutting edge science and determine the potential impact of new research on medical thinking and practice. The ideal candidate will have a sense of urgency to thrive in a dynamic and fast-paced team environment, must be well-organized, able to both develop project strategies and execute project details. The Fellow should be proactive, confident, and personable, and must be willing to learn how to maneuver themselves in a matrixed organizational structure. Candidates must possess ethical standards of the highest level and be willing to comply with all relevant ethical, regulatory, and legal standards.

BENEFITS AND COMPENSATION

As a Northeastern University employee, the fellow will be provided with a competitive salary and benefits package, including the opportunity for tuition waiver benefits. Northeastern is committed to providing faculty and staff with comprehensive benefit programs that enable them to invest in their health and well-being. A full description of available Northeastern benefits may be found here.

9

http://www.northeastern.edu/hrm/benefits/index.html

10

“ It is an incredible experience to be a part of a company pioneering and leading the development of a brand new class of medicines, RNA interference. The fast pace and sense of urgency at Alnylam is conducive to an ideal Fellowship learning environment that keeps you on your toes. Additionally, the ability to teach at Northeastern and participate in scholarly activities with faculty members and students round out a diverse Fellowship experience”

- Alex Wei, Current Pharm.D. Fellow

Dr. Wei graduated from the Ernest Mario School of Pharmacy at Rutgers University in 2015. He is actively involved in Industry Pharmacists Organization and serves as Director of the National Fellows Community. As a student, Dr. Wei was involved in several student organizational leadership positions both locally and nationally. His industry work/rotational experience includes AgencyRx, Janssen, McCann Managed Markets, Bristol-Myers Squibb, and ImClone Systems. While at school he worked part-time as a pharmacy intern at Memorial Sloan Kettering Cancer Center.

MEDICAL AFFAIRS FELLOWSHIP PROGRAM OVERVIEW

SAMPLE YEAR 1 SAMPLE YEAR 2

CORE ROTATION (8 wks)

ELECTIVE ROTATION (8 wks)

CORE ROTATION (8 wks)

CORE ROTATION (8 wks)

CORE ROTATION (8 wks)

THERAPEUTIC OR FUNCTIONAL AREA FOCUS BASED ON

FELLOW’S INTEREST (10 mos)

ELECTIVE ROTATION (8 wks)

11

“At Alnylam, the Fellow will be immersed in a company that has a culture of excellence, commitment to patients and a sense of urgency. All departments within Alnylam consistently strive to innovate, which especially holds true for Medical Affairs.

The role of Medical Affairs at Alnylam constantly evolves and expands as the company rapidly advances compounds through late-stage clinical development. To train in such an environment will give the Fellow a unique perspective on the biopharmaceutical industry and provide the Fellow with a strong foundation for success in his or her career. ”

- Annie Partisano, Alnylam Fellowship Director

Dr. Partisano is currently a Director of Medical Affairs within Alnylam Pharmaceuticals, leading various publication, medical education, and medical affairs operational initiatives. She earned both her Doctor of Pharmacy degree and Master of Science (Biomedical Regulatory Affairs) from Northeastern University and completed a pharmacy practice residency as well as a drug information and education specialty residency at the University of Rochester - Strong Memorial Hospital and Purdue University and Eli Lilly, respectively. Prior to joining Alnylam, Dr. Partisano held a similar position at Sanofi Oncology (Genzyme) and was a Manager, Regional Medicine (MSL) and Manager, Medical Information at Boehringer Ingelheim Pharmaceuticals. She also has an adjunct faculty appointment at Northeastern University.

ALNYLAM PHARMACEUTICALS NORTHEASTERN UNIVERSITY

Monthly Fellowship Meetings/ Projects/ Recruitment

Seminar teaching opportunities

Development of Medical Affairs Dashboard(s) Elective course development

Development and execution of major projects (i.e. clinical publication)

Research collaboration with Northeastern Faculty

Weekly Medical Affairs company digest Precepting and mentoring students

EXAMPLE LONGITUDINAL ACTIVITIES

12

EXAMPLE ELECTIVE ROTATIONS

• Market Access

• Commercial

• Program Management

• Drug Safety and Pharmacovigilence

• Regulatory Affairs

• Health Economics and Outcomes Research

• Pricing and Reimbursement

EXAMPLE MEDICAL AFFAIRS CORE ROTATIONS

PUBLICATIONS

• Development, implementation and maintenanceof overall Publication Plans

• Draft, review, submit product specific publications

• Coordinate and lead cross-functional publicationplanning meetings

• Actively scan relevant competitive primaryliterature on a regular basis and provide anobjective summary of the articles

• Assemble and communicate a summary ofcompetitive abstracts to be presented at relevantupcoming congresses

• Develop training materials for field medical teamsto address emerging competitive data

MEDICAL COMMUNICATIONS

• Plan and execute medical communications programsthat support the medical affairs strategy inaccordance with local, regional and global regulations

• Participate in the review of medical programsincluding CME and medical grants

• Collaborate with other functions to develop coreclinical materials (slide sets, etc.)

• Manage Medical Affairs activities at scientificcongresses; serve as a key advisor on congress/convention best practices and long term strategy

KOL RELATIONS / MEDICAL SCIENCE LIAISON

• Partner closely with investigators and internalstakeholders to drive patient accrual.

• Identify key opinion leaders and cultivate anetwork of experts for key Alnylam disease areas.

• Conduct and implement a comprehensive diseaseawareness tactical plan within the respective geography.

• Collaborate with health care professionals to identifyopportunities for the development of algorithms andguidelines to facilitate early diagnosis.

• Provide in-depth drug and disease stateinformation to health care providers in therespective geography.

• Serve as a liaison to health care professionalsand professional organizations and disease stateadvocacy groups. Support the efforts of patientsupport groups and educational foundations.

• Provide medical and scientific input into theplanning and execution of advisory boards andwork with physician experts to review speakerpresentations and provide additional medicalbackground where requested.

PROTOCOL REVIEW / CLINICAL TRIAL MANAGEMENT

• Coordination and execution of Scientific ReviewCommittees (SRC) Meetings

• Participate in the review of investigator sponsoredtrials (IST) submitted for SRC review

13

At Northeastern, we make a meaningful impact in both our local communities and the world by using our knowledge and resources as forces of change. Through collaborative approach involving partnerships between government, industry, artist, innovators, scholars, and through the translation of fundamental research into applications, we contribute to economic development and enhance societal well-being.

At Northeastern, we encourage our students to become engaged citizens of the world, confident and resourceful people who realize that their knowledge and actions have positive effects on their own lives and those of others. Students ignite their passion for learning and are exposed to the endless possibilities around them through transformative experiential education. The School of Pharmacy provides a dynamic academic environment to guide and support fellows toward successful careers in the biopharmaceutical industry and offers the opportunity to gain teaching and research experiences in an academic setting. The faculty and Alnylam program leaders mentor fellows according to the fellows’ scholarly and professional interests throughout the two year program. As visiting scholars at the School of Pharmacy, fellows will:

• Participate in teaching courses, seminars and laboratories

• Co-precept students on advanced pharmacy practice experiences

• Create and publish scholarly research and review articles

• Present research at scientific and clinical meetings

• Participate in professional development seminars with other fellows and residents

ABOUT NORTHEASTERN UNIVERSITY

“ The Northeastern/Alnylam partnership provides exciting opportunities for the Fellow to gain valuable experience in academia, and to share their industry experience with our students.”

- Mark A. Douglass, Pharm.D. Northeastern Fellowship Program Director, Associate Clinical Professor Northeastern University

Dr. Douglass is an Associate Clinical Professor at Northeastern University, and joined the faculty in 2002. He earned his Doctor of Pharmacy Degree from the University of Michigan and completed a Pharmacy Practice Residency from the University of Illinois at Chicago. Prior to joining the faculty at Northeastern, Dr. Douglass was an inpatient clinical specialist in internal medicine at Detroit Receiving Hospital and University Health Center in Detroit, Michigan.

APPLICATION DETAILS

Thank you for your interest in the Alnylam Pharmaceuticals Post-Doctoral Pharm.D. Fellowship.

The fellow will be selected on a nationally competitive basis and candidates must have a Doctor of Pharmacy degree from an ACPE-accredited college of pharmacy by June 30, 2016

Candidates who wish to apply must submit their formal application to Northeastern University’s job website no later than December 1, 2015.

Application requirements include:

• Cover Letter & Curriculum Vitae

• Unofficial College transcript (paper or electronic)

• 3 Letters of recommendation (sent directly from the reference’s email)

For posting information or to apply for this position, please visit: http://neu.peopleadmin.com/postings/38273

APPLICATION TIMELINE

Applications will be reviewed on a rolling basis; therefore we strongly encourage applicants to submit their cover letter and CV early due to the competitive nature of the fellowship selection process. Official transcripts will be required if an on-site interview is requested.

The deadline for all application materials is December 1st, 2015

PARTICIPATION AT MIDYEAR

Alnylam will be participating in the Personnel Placement Service (PPS) at the

Application correspondence should be addressed and electronically submitted to:

Mark Douglass, PharmDAssociate Clinical Professor and Northeastern/Alnylam Fellowship Program DirectorSchool of [email protected]

ASHP Midyear Clinical Meeting. Applicants who have submitted a complete application will receive information on scheduling an interview.

http://neu.peopleadmin.com/postings/38273mailto:[email protected]

1

© 2015 Alnylam Pharmaceuticals, Inc.For more information, visit us online at Alnylam.com

ALNY-FELLOWSHIP-BROCHURE-2015ALNY-FELLOWSHIP PRINTER FRIENDLYALNY-FELLOWSHIP-BROCHURE-2015

Button 1: